Opinion on Diabetes and Endocrinology

Published within

« | 1 | 2 | 3 | 4 | 5 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Merck/Schering-Plough: Zocor/Zetia submitted for FDA approval

The launch of the single pill combination of Zocor and Zetia should help Merck & Co [MRK] lessen the impact of the genericization of simvastatin. However, global sales are expected to be significantly lower than peak sales of Zocor, and aggressive promotion will be pivotal in driving uptake.

Published By Datamonitor
19 Nov 2003
CommentWire
CommentWire

Metabolic syndrome: WISE results provide more insight

New studies from WISE show that metabolic syndrome is a powerful predictor of CVD events in women with pre-existing CAD. They also showed that metabolic syndrome, not obesity alone, is a predictor of cardiovascular events. These results increase awareness of the condition and highlight the importance of its diagnosis and treatment.

Published By Datamonitor
19 Feb 2004
CommentWire
CommentWire

Sanofi-Synthelabo: encouraging results for rimonabant

Results of two phase III studies with Sanofi-Synthelabo's [SAN.PA] Acomplia (rimonabant) indicate significant weight loss with improved risk factors and successful smoking cessation within 10 weeks. Due to significant unmet need, Acomplia has the potential to become a global leader in the anti-obesity market.

Published By Datamonitor
11 Mar 2004
Expert View
Expert View

Pharmaceutical companies set to make a significant profit from anti-obesity drugs

By 2012, the anti-obesity drugs market will be worth an estimated $2.5 billion globally, compared to $526 million today. However, new drugs will not be the answer to the growing obesity problem. Datamonitor's Jasjeet Mohain argues that increasing education and awareness of the importance of good diet and exercise will remain crucial to combating obesity...

Published By Datamonitor
21 Jul 2004
CommentWire
CommentWire

Merck / Schering-Plough: price war looms for cholesterol market

The US wholesale prices of Merck and Schering-Plough's new cholesterol lowering treatment, Vytorin, have been announced, following FDA approval of the drug. The low price is deliberate as Vytorin is in direct competition with Pfizer's market leading treatment, Lipitor. In addition, Merck needs to lure patients away from Zocor and onto the new combination drug before Zocor's patent expires in 2006.

Published By Datamonitor
28 Jul 2004
Expert View
Expert View

Tackling obesity in childhood is key to controlling adult epidemic

Adult obesity is associated with morbidity, including hypertension, type 2 diabetes and hyperlipidemia, all resulting in huge healthcare costs. In many obese people, the roots of their ill health can be traced to childhood. Datamonitor's Jasjeet Mohain argues that preventative action in early life may be the best hope for dealing with the present obesity epidemic...

Published By Datamonitor
09 Dec 2004
CommentWire
CommentWire

Novartis: Diovan spreads its wings

New results from the VALUE trial have shown that Diovan lowered the risk of developing diabetes by 23% over a four year period. This is a major advantage for Novartis [NVS], as it offers Diovan the opportunity to distinguish itself from most rival antihypertensives, and seize market share in the early-stage cardiovascular field.

Published By Datamonitor
20 May 2005
ResearchWire
ResearchWire

Children's diet: obesity figures continue to gain weight

Published By Datamonitor
28 Jul 2005
CommentWire
CommentWire

Statins: indications for wider use

A meta-analysis of 14 previous trials has shown that diabetics and anyone at risk of a heart attack or stroke should be prescribed a statin drug, regardless of cholesterol levels. Furthermore, scientists found no evidence of increased cancer risk with statin therapy. These results implicate the already dominant class of drugs for wider usage.

Published By Datamonitor
28 Sep 2005
CommentWire
CommentWire

Obesity: prenatal care presents new eHealth opportunity

A recent Ohio State University study has reported that babies born to overweight women are three times more likely to become overweight themselves. The findings suggest that preventing the growing problem of childhood obesity may need to begin in prenatal care. With online disease management tools gaining in popularity, this could also represent a new area of opportunity for eHealth providers.

Published By Datamonitor
07 Dec 2005

« | 1 | 2 | 3 | 4 | 5 | » »|

No help is available.